論文・技術情報追加のお知らせ

1. Real-world Pharmacovigilance Study of Drug-induced Diabetes Insipidus from the FAERS Database.

FAERS解析による薬剤性尿崩症と関連薬の網羅的評価

対象DB：FAERS

2. Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.

米欧における医薬品・医療機器併用製品の市販後安全性規制の相違

対象DB：FAERS

3. Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a review.

nan

対象DB：EudraVigilance,FAERS

4. Evaluation of the unregulated online kratom market in two east-central European countries: test purchase and analysis of potential toxicological consequences.

東中欧におけるクラトム市場と健康リスク評価

対象DB：FAERS

5. Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality Analysis.

DAGを用いた薬剤安全性シグナル検出の因果的解釈

対象DB：FAERS

6. Vaccine-associated non-scarring immune-mediated alopecia: insights from a pharmacovigilance analysis of the Vaccine Adverse Event Reporting System.

ワクチン関連非瘢痕性免疫性脱毛症の薬剤疫学解析

対象DB：FAERS,VAERS

7. Safety of CDK4/6 inhibitors in older patients: A FAERS-based analysis of serious and fatal adverse events.

高齢乳癌患者におけるCDK4/6阻害薬の安全性解析

対象DB：FAERS

8. Disproportionality analysis of adverse events associated with bimekizumab: a real-world study based on FDA Adverse Event Reporting System (FAERS) Database.

ビメキズマブの市販後安全性シグナル解析

対象DB：FAERS

9. Cardiotoxicity associated with antifungal agents: A pharmacovigilance analysis of the FDA Adverse Event Reporting System.

FAERSを用いた抗真菌薬の心毒性評価

対象DB：FAERS

10. A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase.

VigiBaseを用いたBTK阻害薬の安全性評価

対象DB：FAERS,VigiBase

11. Pharmacovigilance assessment of adverse events following yellow fever vaccination: Disproportionality analysis of VAERS reports, 2015-2025.

VAERSによる黄熱ワクチン重篤有害事象の評価

対象DB：FAERS,VAERS

12. Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.

FAERS・JADERによるフィブラート系薬関連胆道有害事象解析

対象DB：FAERS,JADER

13. Drug-induced polycystic ovary syndrome: a real-world pharmacovigilance study based on the FAERS database.

FAERSを用いた薬剤関連多嚢胞性卵巣症候群シグナル解析

対象DB：FAERS

14. Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.

FAERS・JADERを用いたPPI感染関連有害事象シグナル解析

対象DB：FAERS,JADER

15. The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis.

イサツキシマブ関連新規有害事象の薬剤疫学的検出

対象DB：FAERS

16. Systematic analysis of adverse reactions associated with dantrolene treatment: From clinical features to molecular mechanisms.

ダントロレン関連有害事象の薬剤疫学と分子機序解析

対象DB：CVAR,FAERS,JADER

17. Pharmacovigilance assessment of ropivacaine safety using FAERS data (2004-2024).

ロピバカイン関連有害事象の実世界薬剤安全性解析

対象DB：FAERS

18. Analyzing adverse event signals of aprepitant using FAERS database data in real-world settings: Broadening the adverse event spectrum of aprepitant and its clinical implications.

アプレピタント関連有害事象の網羅的薬剤疫学解析

対象DB：FAERS

19. Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database.

ベダキリン等新規抗結核薬の有害事象解析

対象DB：FAERS

20. Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data.

乳児における主要抗菌薬の安全性：FAERS解析

対象DB：FAERS

21. Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database.

結核治療におけるレボフロキサシンとモキシフロキサシン併用療法の安全性比較

対象DB：FAERS

22. Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy.

非扁平上皮肺癌におけるアテゾリズマブ併用療法の副作用比較

対象DB：FAERS

23. Association of aggression and anti-seizure medications in pediatric patients: Disproportionality analysis using the FDA adverse event reporting system.

小児てんかんにおける抗てんかん薬と攻撃性の関連

対象DB：FAERS

24. Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database.

医薬品副作用の世界的負担と予防戦略の最新動向

対象DB：JADER

25. Signal detection in pharmacovigilance: Methods, tools, and workflows from case identification to adverse drug reaction database entry.

nan

対象DB：EudraVigilance,VigiBase

26. Loa loa Encephalopathy Following Treatment With Benzimidazole Derivatives: A Systematic Review.

ロイア症におけるベンズイミダゾール関連脳症の安全性懸念

対象DB：VigiBase

27. Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database.

レボドパ副作用における性差の薬剤疫学的解析

対象DB：VigiBase

28. Effectiveness of rehabilitation dose heterogeneity for improving functional outcomes of patients with acute stroke: a nationwide observational study.

急性期脳梗塞における高強度リハビリ効果の個別差

対象DB：DPC

29. Nationwide Analysis of Spontaneous Coronary Artery Dissection-Related Acute Myocardial Infarction in Japanese Patients Aged =60 Years Using the Administrative JROAD-DPC Database.

自然冠動脈解離による急性心筋梗塞の臨床像

対象DB：DPC

30. Regional equity and declining laryngeal surgery in Japan: A nationwide claims-based analysis from 2014 to 2022.

日本における耳鼻咽喉科手術の全国動向解析

対象DB：NDB

31. Seasonality of Sensorineural Hearing Loss and Impact of the Coronavirus Disease 2019 Pandemic.

突発性難聴発症の季節性とCOVID-19流行の影響

対象DB：NDB

32. Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis.

潰瘍性大腸炎における先進治療と血栓・心血管リスク

対象DB：MDV

33. Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the Clinical Practice Research Datalink (CPRD).

英国EHRを用いたSCCSによる安全性シグナル検出

対象DB：CPRD

34. Clinical implications of intentional weight loss in people living with type 2 diabetes: A real-world database study.

2型糖尿病肥満者での減量と血管合併症リスク

対象DB：CPRD

35. The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD).

英国一次医療での片頭痛急性期治療薬の使用実態

対象DB：CPRD

36. Risk prediction in people with acute myocardial infarction in England: a cohort study using data from 1521 general practices.

心筋梗塞後短期予後を予測する一次医療モデルを開発

対象DB：CPRD